Evergenbio.com listed on Chaos ransomware leak site

• Ransomware group: Chaos
• Country: United States
• Sector: Healthcare
• Announcement date: September 6, 2026

Chaos ransomware group claims data breach at Evergenbio.com

The threat actor known as Chaos has listed the organization evergenbio.com on its leak site. This announcement, which appeared on September 6, 2026, serves as a claim by the group that they have successfully obtained data belonging to the company. At this stage, public information regarding the specific operations and background of the Chaos group remains limited.

Details of the claimed incident

According to the announcement published by the threat actor, the incident was reported on September 6, 2026. The group has claimed to have access to data belonging to the target organization, though the specific circumstances surrounding the initial intrusion have not been detailed in the public announcement. In many ransomware scenarios, threat actors utilize leak sites to pressure organizations through double extortion, a tactic where stolen data is threatened to be released publicly if a ransom is not paid. While the specific mechanics of this particular claim are not detailed, the listing confirms the group's intent to publicize the alleged breach.

Information regarding the leaked data

Regarding the specific contents of the alleged breach, the listing provides no details regarding the nature of the data that has been purportedly taken. No specific file types, data volumes, or specific categories of information have been identified in the group's announcement. The listing names no data types.

About Evergen

Evergen is a Contract Development and Manufacturing Organization (CDMO) that specializes in biomaterial solutions for regenerative medicine. The company operates by collaborating with OEM partners to provide customized biomaterial solutions that are tailored to meet specific clinical needs.

Potential impact and industry implications

Given the specialized nature of Evergen's operations in the fields of biomaterials and regenerative medicine, a potential data breach of this nature could expose sensitive clinical and commercial information. Because the organization is based in the United States, such an incident may trigger legal proceedings under regulations designed to protect health data, such as HIPAA.

The publication of sensitive information could lead to several significant consequences for an organization in this sector:

• Commercial relationships: The release of proprietary information could harm the organization's existing commercial relationships with its OEM partners.
• Supply chain security: Such an incident may undermine the overall security and integrity of the supply chain.
• Secondary attacks: The leaked data could potentially be utilized by malicious actors for identity theft or for conducting targeted phishing attacks against the organization or its partners.

For organizations operating within the healthcare and biotechnology sectors, maintaining robust defensive postures is critical. Common defensive steps include implementing strict access controls, maintaining comprehensive logging and monitoring to detect unauthorized movement, and ensuring that all clinical and commercial data is encrypted both at rest and in transit. Furthermore, managing third-party risks is essential for companies that rely on OEM partnerships to maintain supply chain integrity.